Jul. 22 – Israel drug delivery systems developer Oramed Pharmaceuticals, has reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients.

The completion of this study marks Oramed’s first clinical trial on patients with type 1 diabetes Mellitus. In the trial, Oramed’s oral capsule, was well tolerated by patients and no serious adverse events were observed.

The insulin absorption was not affected when given before meal ingestion. Jerusalem-based Oramed, which was founded in 2006, is now conducting a Phase 2B clinical trial in South Africa, on type 2 diabetic patients. The company’s technology is based on over 25 years of research by scientists at Jerusalem’s Hadassah Medical Center.